Create Account | Sign In: Author or Forum

 
News  |  Journals  |  Conferences  |  Opinion  |  Articles  |  Forums  |  Twitter    
 
Category: Gastroenterology | Oncology | Pharmacy | Geriatrics | Journal

Back to Journal Articles

No Benefit Seen for Adjuvant Oxaliplatin in Stage II Colon CA

Last Updated: August 21, 2012.

 

Subgroup analysis shows no survival benefit for adjuvant oxaliplatin in elderly or stage II disease

Share |

Comments: (0)

Tell-a-Friend

 

  Related
 
For elderly patients with colon cancer or those with stage II disease, the addition of oxaliplatin to fluorouracil with leucovorin does not seem to offer any survival benefit, according to a study published online Aug. 20 in the Journal of Clinical Oncology.

TUESDAY, Aug. 21 (HealthDay News) -- For elderly patients with colon cancer or those with stage II disease, the addition of oxaliplatin to fluorouracil with leucovorin (FL) does not seem to offer any survival benefit, according to a study published online Aug. 20 in the Journal of Clinical Oncology.

Christophe Tournigand, M.D., Ph.D., from the Hôpital Saint-Antoine in Paris, and colleagues conducted subgroup analyses of stage II colon cancer and elderly patients with colon cancer, who were randomly assigned to FL with or without oxaliplatin (FOLFOX4).

The researchers found that 889 patients had stage II disease, including 569 high-risk and 330 low-risk patients, and 315 patients were aged 70 to 75 years. Comparing FOLFOX4 with FL, the hazard ratios (HRs) for stage II patients were not significant for disease-free survival (DFS) or overall survival (OS), and no interaction was noted between treatment and age or stage. There was no benefit seen for low-risk stage II patients. For high-risk stage II patients and for elderly patients, the HRs comparing FOLFOX4 with FL were not significant for DFS or OS.

"The addition of oxaliplatin to infusional fluorouracil/leucovorin has not been shown to be beneficial in low-risk or high-risk stage II patients or for patients between 70 and 75 years," the authors write. "The identification of a patient population for which adjuvant therapy is necessary, safe, and effective continues to be challenging, especially for high-risk stage II patients and for elderly patients."

Several authors disclosed financial ties to the pharmaceutical industry.

Abstract
Full Text (subscription or payment may be required)
Editorial

Copyright © 2012 HealthDay. All rights reserved.


Previous: Azathioprine May Benefit Pediatric Atopic Dermatitis Next: Study Identifies Sleep Apnea in 50 Percent of Women

Reader comments on this article are listed below. Review our comments policy.


Submit your opinion:

Name:

Email:

Location:

URL:

Remember my personal information

Notify me of follow-up comments?

advertisement.gif (61x7 -- 0 bytes)
 

Are you a Doctor, Pharmacist, PA or a Nurse?

Join the Doctors Lounge online medical community

  • Editorial activities: Publish, peer review, edit online articles.

Doctors Lounge Membership Application

 
     

 advertisement.gif (61x7 -- 0 bytes)

 

 

Useful Sites
MediLexicon
  Tools & Services: Follow DoctorsLounge on Twitter Follow us on Twitter | RSS News | Newsletter | Contact us
Copyright © 2001-2014
Doctors Lounge.
All rights reserved.

Medical Reference:
Diseases | Symptoms
Drugs | Labs | Procedures
Software | Tutorials

Advertising
Links | Humor
Forum Archive
CME | Conferences

Privacy Statement
Terms & Conditions
Editorial Board
About us | Email

This website is certified by Health On the Net Foundation. Click to verify. This site complies with the HONcode standard for trustworthy health information:
verify here.